Substance Use Disorder

PleoPharma secures $6.5M NIDA grant to advance phase 3 PP-01 trial, aiming to ease cannabis withdrawal and address untreated cannabis use disorder.

Long-acting injectable buprenorphine cuts missed doses, boosts retention, and protects patients during high-risk transitions in the fentanyl era.

Urine drug screenings are often misordered and misread, risking stigma and harm; learn immunoassay limits, confirmatory testing basics, and when testing truly helps.

Emerging evidence shows eating disorders in male athletes are widely underrecognized, as screening tools built around female presentations overlook muscularity-driven behaviors like compulsive exercise, rigid dieting, and supplement misuse.

Why teens use drugs and alcohol: avoidant attachment and emotional isolation fuel addiction; attachment-based therapy rebuilds bonds and cuts relapse.

Share insights on substance use care—practice tips, research, and cases—for Psychiatric Times’ July 2026 series. Pitch your article today.

FDA issues CRL for cytisinicline, citing manufacturing issues.

Why schizophrenia shortens life: smoking, metabolic risks, and care gaps drive a 15-year mortality loss—and clinicians can help close it.

GLP-1 drugs like semaglutide may curb alcohol and opioid cravings, as trials expand, combos emerge, and interaction risks surface.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

ASAM’s new youth SUD criteria help clinicians deliver developmentally tailored, prevention-first care with coordinated family and community supports.